BridGene Biosciences’ IMTAC ™ Small Molecule Discovery Platform Featured in Multiple Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

SAN JOSE, Calif.: SAN JOSE, Calif., Oct. 7, 2021 /PRNewswire/ -- BridGene Biosciences, Inc., a biotechnology company using a unique chemoproteomic technology to discover and develop small molecules for high value, traditionally undruggable targets, disclosed today research findings from five scientific presentations at the 2021 AACR-NCI-EORTC Virtual International Conference on...

Click to view original post